CAR-T boxed warnings: What comes next?
The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials.
In today’s episode, Fierce Pharma’s Angus Liu talks with regulatory experts Mwango Kashoki, M.D., and Steve Winitsky, M.D., to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line.
Related Insights
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
CTB Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
CTB Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025